Ventyx Biosciences (NASDAQ:VTYX) Price Target Cut to $11.00

Ventyx Biosciences (NASDAQ:VTYX) had its price target trimmed by Wells Fargo & Company from $16.00 to $11.00 in a report issued on Monday, Benzinga reports. The firm currently has an overweight rating on the stock.

VTYX has been the topic of a number of other reports. Canaccord Genuity Group dropped their target price on shares of Ventyx Biosciences from $15.00 to $14.00 and set a buy rating on the stock in a research note on Monday. HC Wainwright restated a neutral rating and issued a $6.00 target price on shares of Ventyx Biosciences in a research note on Tuesday, July 30th. Finally, Oppenheimer dropped their target price on shares of Ventyx Biosciences from $12.00 to $10.00 and set an outperform rating on the stock in a research note on Thursday, June 6th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Ventyx Biosciences currently has a consensus rating of Moderate Buy and an average price target of $8.29.

Ventyx Biosciences Trading Up 0.5 %

Shares of NASDAQ:VTYX opened at $1.92 on Monday. The company has a market capitalization of $135.36 million, a price-to-earnings ratio of -0.59 and a beta of 0.39. Ventyx Biosciences has a 12 month low of $1.87 and a 12 month high of $38.20. The firm’s 50-day moving average is $2.49 and its 200 day moving average is $4.14.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.12. As a group, equities analysts forecast that Ventyx Biosciences will post -2.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Ventyx Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Deerfield Management Company L.P. Series C boosted its stake in shares of Ventyx Biosciences by 64.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock valued at $13,466,000 after purchasing an additional 2,287,570 shares in the last quarter. Farallon Capital Management LLC bought a new position in shares of Ventyx Biosciences during the first quarter valued at approximately $17,435,000. Redmile Group LLC boosted its stake in shares of Ventyx Biosciences by 944.4% during the first quarter. Redmile Group LLC now owns 2,164,126 shares of the company’s stock valued at $11,903,000 after purchasing an additional 1,956,923 shares in the last quarter. Opaleye Management Inc. boosted its stake in shares of Ventyx Biosciences by 12.7% during the first quarter. Opaleye Management Inc. now owns 1,285,000 shares of the company’s stock valued at $7,068,000 after purchasing an additional 145,000 shares in the last quarter. Finally, First Light Asset Management LLC purchased a new stake in Ventyx Biosciences during the first quarter valued at approximately $3,437,000. 97.88% of the stock is currently owned by institutional investors.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.